CYNK-201 / Celularity - LARVOL DELTA

Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells Preferentially Eliminate Senescent Cells Derived from a Tumor Model (ASGCT 2024) - "Celularity is developing human placental CD34+-derived, cryopreserved, off-the-shelf, allogeneic NK cell products non-modified (CYNK-001), or genetically modified to optimize persistence and efficacy (CYNK-201) for the treatment of tumors and age-related diseases...With CYNK-001, there was significantly increased cytolysis of etoposide or doxorubicin treated cells vs. cytolysis of control non-treated A549 cells...Consistently, significantly increased secretion of inflammatory cytokines GM-CSF, G-CSF, IFN-γ, and TNF-α was also observed following CYNK co-culture with chemo-induced senescent A549 cells compared to non-treated cells, further confirming the preferential senolysis.Our preclinical data indicates that CYNK cells could serve as potent and selective senolytic agent for age-related diseases and also following conventional cancer treatment, CYNK may improve overall therapeutic outcomes and delay disease recurrence. Further investigation of CYNK cells in this regard,..."

Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD34 • CD58 • CSF2 • CXCL8 • IFNG • IL15 • IL6 • NCAM1 • NKG2D • TNFA

Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells (GlobeNewswire) - "The preclinical data, which suggest that Celularity’s placenta-derived unmodified natural killer (NK) cells (CYNK-001) and genetically modified NK cells (CYNK-201) may serve as potent and selective senolytic agents for use in addressing age-related diseases, will be presented on May 9, 2024....Celularity believes these preclinical data demonstrate the potential of its assets to target and selectively remove damaged and abnormal cells expressing stress ligands, such as senescent, virally infected and cancer cells."

Preclinical • Oncology

Developing human placental CD34-derived natural killer cells with high affinity and cleavage resistant CD16 and secreted IL-15 (CYNK-201) for cancer immunotherapy (SITC 2023) - "ADCC activity of CYNK-201 against HER2+ gastric cancer cell line NCI-N87 and CD20+ Burkitts lymphoma cell line Daudi was assessed in combination with trastuzumab and rituximab, respectively. Conclusions Our results demonstrated enhanced in vitro ADCC, in vivo persistence and anti-tumor activity of CYNK-201. Further development of CYNK-201 is warranted."

IO biomarker • Burkitt Lymphoma • Gastric Cancer • Gastrointestinal Cancer • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor • CD20 • CD34 • HER-2 • IL15 • NCAM1 • NKG2D